// App-Quantinova.ai

2019 : Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

Researchers

Presenter

  • Wolfgang Wick

Principal Investigators

  • Thierry Gorlia

  • Martin Bendszus

  • Felix Sahm

  • Jacoline E Bromberg

  • Alba Ariela Brandes

  • Maaike J Vos

  • Julien Domont

  • Ahmed Idbaih

  • Jean-Sebastien Frenel

  • Paul M. Clement

  • Michel Fabbro

  • Emilie Le Rhun

  • Francois Dubois

  • Davide Musmeci

  • Michael Platten

  • Vassilis Golfinopoulos

  • Martin J. Van Den Bent

Medical Centers

  • Neurology Clinic, Heidelberg, Germany

  • University of Lausanne Hospitals, Lausanne, Switzerland

  • European Organisation for Research and Treatment of Cancer, Bruxels, Belgium

  • Heidelberg University Hospital, Heidelberg, Germany

  • Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany

  • Erasmus MC, Rotterdam, Netherlands

  • Azienda USL Bellaria-Maggiore Hospital, Bologna, Italy

  • Medisch Centrum Haaglanden, The Hague, Netherlands

  • Institut Gustave-Roussy, Villejuif, France

  • Universite Pierre et Marie Curie Paris VI, Paris, France

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • UZ Leuven-Gasthuisberg, Leuven, Belgium

  • CRLC Val d'Aurelle, Montpellier, France

  • Centre Oscar Lambret, Lille, France

  • CHRU, Lille, France

  • EORTC HQ, Brussels, Belgium

  • Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany

  • European Organisation for Research and Treatment of Cancer, Bruxels, Belgium

  • Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands

Locations

  • Italy

  • Netherlands

  • Germany

  • Switzerland

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Temozolomide

  • Bevacizumab

  • Lomustine

Outcome

  • Indeterminate

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01290939

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved